Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low‐dose cyclophosphamide and anti‐thymocyte globulin | Zendy

Ayas M. | Zendy; AlMusa A. | Zendy; AlJefri A. | Zendy; AlSeraihi A. | Zendy; AlMahr M. | Zendy; Rifai S. | Zendy; ElSolh H. | Zendy

Premium

Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low‐dose cyclophosphamide and anti‐thymocyte globulin

Author(s) -

Ayas M.,

AlMusa A.,

AlJefri A.,

AlSeraihi A.,

AlMahr M.,

Rifai S.,

ElSolh H.

Publication year - 2007

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.20696

Subject(s) - dyskeratosis congenita , medicine , cyclophosphamide , regimen , bone marrow failure , anti thymocyte globulin , conditioning regimen , transplantation , stem cell , oncology , gastroenterology , chemotherapy , haematopoiesis , dna , genetics , telomere , biology

Bone marrow failure is the major cause of early mortality in patients with dyskeratosis congenita (DC); early trials with conventional conditioning regimens were associated with remarkable chronic morbidity and mortality, and the optimal conditioning regimen for these patients remains undetermined. We report a case of a child afflicted with DC who underwent related full HLA‐matched stem cell transplant (SCT) using a regimen of low dose cyclophosphamide and antithymocyte globulin (ATG). The regimen was well tolerated and associated with no significant short‐term toxicity. Pediatr Blood Cancer 2007;49:103–104. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research